Sign in

DDDD on London Stock Exchange

4D Pharma

4D Pharma is a pharmaceutical company based in Leeds, founded in 2014.1 Its shares trade on London Stock Exchange under the symbol DDDD.1

Price unavailable

Last updated Oct 21, 2026.

Overview

$718.0KRevenue, fiscal 20214
-$31.9MNet income, fiscal 20214
2014Founded1

Compare with Lexaria Bioscience Corp., Summit Therapeutics or Unicycive Therapeutics, Inc., or pick any stock.

  • TickerDDDD on London Stock Exchange1
  • Industrypharmaceutical industry1
  • HeadquartersLeeds1
  • Websitewww.4dpharmaplc.com
  • Legal formpublic limited company1
  • Incorporated inUnited Kingdom5
  • Business address9 Bond Court, Leeds, X0 Ls1 2Jz5
  • Filer categoryNon-accelerated filer, Emerging growth company5
  • LEI213800O49VYSXWE2ZD523
  • StatusInactive3
  • LEI statusRetired3
  • Registered addressC/O INTERPATH ADVISORY, LS1 4DP Leeds, United Kingdom3
  • Registered withCompanies House, 088405793

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-5189.6%Operating margin4
-4448.2%Net margin4
4.1%Revenue growth, 20214
-98.5%Return on equity4
0.37×Debt to equity4
-$38.2MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development57¢$21.6M
  • Selling, general and admin42¢$15.9M
  • Interest2¢$581.0K
  • Income tax0¢$22.0K

Out of $718.0K in revenue.4 The company lost money this year.

Financial statements

Revenue4$718.0K in 2021+167% since 2019
0$200.0K$400.0K$600.0K$800.0K2019: $269.0K$269.0K20192020: $690.0K$690.0K2020+157%2021: $718.0K$718.0K2021+4%
Operating income64-$37.3M in 2021−4% since 2018
-$60.0M-$40.0M-$20.0M02018: -$38.9M-$38.9M20182019: -$40.3M-$40.3M2019+4%2020: -$35.0M-$35.0M2020−13%2021: -$37.3M-$37.3M2021+6%
Net income64-$31.9M in 2021−2% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$32.6M-$32.6M20182019: -$30.3M-$30.3M2019−7%2020: -$30.5M-$30.5M2020+1%2021: -$31.9M-$31.9M2021+5%
Fiscal year20172018201920202021
Revenue$269.0K4$690.0K4$718.0K4
Research and development$27.8M6$29.2M4$23.4M4$21.6M4
Selling, general and admin$11.3M6$10.4M4$13.0M4$15.9M4
Operating expenses$38.0M4
Operating income-$38.9M6-$40.3M4-$35.0M4-$37.3M4
Interest$3.0K6$78.0K7$6.0K7$581.0K4
Income before tax-$32.0M4
Income tax-$13.0K4-$22.0K4
Net income-$32.6M6-$30.3M4-$30.5M4-$31.9M4

Compare 4D Pharma with another company

Corporate structure

4D Pharma sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of 4D Pharma

  • Steven Michael Oliveira Filed SC 13G/A on 4D Pharma, latest Mar 2, 2022 (2 filings since Feb 3, 2022)
  • Duncan Peyton Filed SC 13G on 4D Pharma, latest Feb 28, 2022
  • Alexander Stevenson Filed SC 13G on 4D Pharma, latest Feb 25, 2022
  • Merck & Co. Filed SC 13G on 4D Pharma, latest Feb 2, 2022
  • 4D Pharma Leeds, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What 4D Pharma reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$10.0M4 Dec 31, 2021$10.7M4 Dec 31, 2020−6.3%
Accumulated depreciation$6.0M4 Dec 31, 2021$5.6M4 Dec 31, 2020+7.7%
Property and equipment, net$4.0M4 Dec 31, 2021$5.1M4 Dec 31, 2020−21.8%
Operating-lease assets (leased space)$906.0K4 Dec 31, 2021$1.1M4 Dec 31, 2020−19.8%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$21.0M4 Dec 31, 2021$12.0M4 Dec 31, 2020+74.9%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$13.0M4 Dec 31, 2021$13.5M4 Dec 31, 2020−3.5%
Intangible assets, net (excluding goodwill)$6.1M4 Dec 31, 2021$6.3M4 Dec 31, 2020−2.8%
Finite-lived intangibles, gross$8.0M4 Dec 31, 2021$8.0M4 Dec 31, 2020−0.9%
Accumulated amortization-$1.8M4 Dec 31, 2021-$1.7M4 Dec 31, 2020−5.8%
Finite-lived intangibles, net$27.0K4 Dec 31, 2021$6.3M6 Dec 31, 2020−99.6%

Timeline

  1. Feb 18, 2014Went public Listed on London Stock Exchange1
  2. 2014Founded Founded1

Filings

51 filings to the SEC since October 2021: 1 annual reports, 5 large holders, 45 other. The latest 20:

  1. Feb 23, 20236-K EDGAR
  2. Feb 17, 20236-K EDGAR
  3. Feb 7, 20236-K EDGAR
  4. Jan 3, 20236-K EDGAR
  5. Nov 18, 20226-K EDGAR
  6. Nov 15, 20226-K EDGAR
  7. Oct 7, 20226-K EDGAR
  8. Sep 30, 20226-K EDGAR
  9. Aug 24, 20226-K EDGAR
  10. Aug 24, 20226-K EDGAR
  11. Aug 24, 20226-K EDGAR
  12. Jul 5, 20226-K EDGAR
  13. Jun 29, 20226-K EDGAR
  14. Jun 24, 20226-K EDGAR
  15. Jun 24, 20226-K EDGAR
  16. Jun 1, 20226-K EDGAR
  17. Apr 28, 2022EFFECT EDGAR
  18. Apr 26, 2022CORRESP EDGAR
  19. Apr 26, 2022UPLOAD EDGAR
  20. Apr 21, 2022F-3 EDGAR

The 51 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Steven Michael OliveiraSC 13G/A, 2 filings Feb 3, 2022 to Mar 2, 20228
  • Duncan PeytonSC 13G, 1 filing Feb 28, 20229
  • Alexander StevensonSC 13G, 1 filing Feb 25, 202210
  • Merck & Co.SC 13G, 1 filing Feb 2, 202211

SEC filer profile

How 4D Pharma is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAR4D Pharma PLC2
  • CIK0001830162
  • Filer statusNon-accelerated filer<br>emerging growth company2
  • Incorporated inUnited Kingdom2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address9 Bond Court, Leeds, X0 LS1 2JZ2
  • Phone44-0-113-895-01302
  • Shares outstanding180,300,967 as of Dec 31, 20214
  • On EDGAR sinceNov 25, 20202
  • Filings111 in all: 6-K (35), 424B3 (11), 425 (10), CORRESP (10), EFFECT (7), UPLOAD (7), F-4/A (5), SC 13G (4)2
    All 24 form types

    20-F (2), F-1 (2), F-3 (2), S-8 (2), SC 13G/A (2), SEC STAFF LETTER (2), 20-F/A (1), 25-NSE (1), 6-K/A (1), 8-A12B (1), CERT (1), F-1/A (1), F-3/A (1), F-4 (1), F-6 (1), POS AM (1)

  • Latest filingsAnnual report (20-F) Mar 31, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11